Artiva Biotherapeutics, Inc.
4 clinical trials · Sponsor
◉ Watch Artiva Biotherapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. (NCT06991114) | Artiva Biotherapeutics, Inc. | 2025-07-09 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus (NCT06265220) | Artiva Biotherapeutics, Inc. | 2024-04-03 |
| A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors (NCT05678205) | Artiva Biotherapeutics, Inc. | 2023-08-01 |
| AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT04673617) | Artiva Biotherapeutics, Inc. | 2021-03-29 |
Track Artiva Biotherapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.